Mark Kirschbaum - 31 Jan 2023 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Reporting relationship: Chief Medical Officer
Issuer ticker: CYCC
Reported as of: 31 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2023, 15:17:17 UTC
Prior SEC filing: 15 Dec 2021
Next SEC filing: 03 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Mark Kirschbaum

Key filing fact

Mark Kirschbaum filed Form 4 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 02 Feb 2023.

Key facts

This page summarizes Mark Kirschbaum's Form 4 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Feb 2023, 15:17.

Change

Previous filing in this sequence was filed on 15 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYCC transaction

Common Stock

Award

Transaction value: $0
Shares: +31,200
Change %
Price: $0.000000
Shares after: 31,200
Date: 31 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person received an award of 31,200 restricted stock units on January 31, 2023, which shall vest in full on January 31, 2026, provided, however, that if certain clinical milestones are achieved then such restricted stock units shall vest in full earlier in connection with such achievement.